Results from a new phase 1 trial indicate that immunotherapy could be used to treat the most common form of colorectal cancer, also known as bowel cancer. Consistent responses to immunotherapy have been reported in patients with the most common type of colorectal tumors, known as MSS mCRC, with 61% of patients seeing their tumor shrink or remain stable after receiving treatment.
Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.
Iovance Biotherapeutics : IOV COM 202 Cohort 1A ASCO 2024 Oral Presentation marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Half-Matched Family Donors Offer Best Outcomes for Hispanic Patients Undergoing Bone Marrow Transplants onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.